Astra, Lilly stick with Alzheimer's approach despite setback

FRANKFURT, Dec 9 (Reuters) - AstraZeneca will expand its collaboration with Eli Lilly to develop an experimental Alzheimer's drug, sticking with an approach that has been a mainstay of research despite recent setbacks.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.